173 related articles for article (PubMed ID: 35156326)
41. Developments in targeted therapy in melanoma.
Amann VC; Ramelyte E; Thurneysen S; Pitocco R; Bentele-Jaberg N; Goldinger SM; Dummer R; Mangana J
Eur J Surg Oncol; 2017 Mar; 43(3):581-593. PubMed ID: 27923592
[TBL] [Abstract][Full Text] [Related]
42. MEK inhibitors for the treatment of NRAS mutant melanoma.
Sarkisian S; Davar D
Drug Des Devel Ther; 2018; 12():2553-2565. PubMed ID: 30154648
[TBL] [Abstract][Full Text] [Related]
43. Melanoma Progression Inhibits Pluripotency and Differentiation of Melanoma-Derived iPSCs Produces Cells with Neural-like Mixed Dysplastic Phenotype.
Castro-Pérez E; Rodríguez CI; Mikheil D; Siddique S; McCarthy A; Newton MA; Setaluri V
Stem Cell Reports; 2019 Jul; 13(1):177-192. PubMed ID: 31231022
[TBL] [Abstract][Full Text] [Related]
44. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
Hutchinson KE; Lipson D; Stephens PJ; Otto G; Lehmann BD; Lyle PL; Vnencak-Jones CL; Ross JS; Pietenpol JA; Sosman JA; Puzanov I; Miller VA; Pao W
Clin Cancer Res; 2013 Dec; 19(24):6696-702. PubMed ID: 24345920
[TBL] [Abstract][Full Text] [Related]
45. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
Samlowski W; Adajar C
BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
[TBL] [Abstract][Full Text] [Related]
46. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
47. Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma.
Hong A; Moriceau G; Sun L; Lomeli S; Piva M; Damoiseaux R; Holmen SL; Sharpless NE; Hugo W; Lo RS
Cancer Discov; 2018 Jan; 8(1):74-93. PubMed ID: 28923912
[TBL] [Abstract][Full Text] [Related]
48. Targeted therapies for cutaneous melanoma.
Kee D; McArthur G
Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943
[TBL] [Abstract][Full Text] [Related]
49. Targeted Therapy for Melanoma.
Wong DJ; Ribas A
Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
[TBL] [Abstract][Full Text] [Related]
50. Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.
Liu D; Liu X; Xing M
Cell Cycle; 2014; 13(2):208-19. PubMed ID: 24200969
[TBL] [Abstract][Full Text] [Related]
51. Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma.
Verykiou S; Alexander M; Edwards N; Plummer R; Chaudhry B; Lovat PE; Hill DS
Br J Dermatol; 2019 Feb; 180(2):346-356. PubMed ID: 30339727
[TBL] [Abstract][Full Text] [Related]
52. Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era.
Wattson DA; Sullivan RJ; Niemierko A; Merritt RM; Lawrence DP; Oh KS; Flaherty KT; Shih HA
J Neurooncol; 2015 May; 123(1):75-84. PubMed ID: 25864098
[TBL] [Abstract][Full Text] [Related]
53. ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.
Richard G; Dalle S; Monet MA; Ligier M; Boespflug A; Pommier RM; de la Fouchardière A; Perier-Muzet M; Depaepe L; Barnault R; Tondeur G; Ansieau S; Thomas E; Bertolotto C; Ballotti R; Mourah S; Battistella M; Lebbé C; Thomas L; Puisieux A; Caramel J
EMBO Mol Med; 2016 Oct; 8(10):1143-1161. PubMed ID: 27596438
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic targets in melanoma: map kinase pathway.
Haluska FG; Ibrahim N
Curr Oncol Rep; 2006 Sep; 8(5):400-5. PubMed ID: 16901402
[TBL] [Abstract][Full Text] [Related]
55. Role of dual specificity phosphatases (DUSPs) in melanoma cellular plasticity and drug resistance.
Singh MK; Altameemi S; Lares M; Newton MA; Setaluri V
Sci Rep; 2022 Aug; 12(1):14395. PubMed ID: 35999349
[TBL] [Abstract][Full Text] [Related]
56. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.
Czarnecka AM; Teterycz P; Mariuk-Jarema A; Lugowska I; Rogala P; Dudzisz-Sledz M; Switaj T; Rutkowski P
Target Oncol; 2019 Dec; 14(6):729-742. PubMed ID: 31754963
[TBL] [Abstract][Full Text] [Related]
57. Targeted therapy resistance mechanisms and therapeutic implications in melanoma.
Chen G; Davies MA
Hematol Oncol Clin North Am; 2014 Jun; 28(3):523-36. PubMed ID: 24880945
[TBL] [Abstract][Full Text] [Related]
58. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
59. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
Van Allen EM; Wagle N; Sucker A; Treacy DJ; Johannessen CM; Goetz EM; Place CS; Taylor-Weiner A; Whittaker S; Kryukov GV; Hodis E; Rosenberg M; McKenna A; Cibulskis K; Farlow D; Zimmer L; Hillen U; Gutzmer R; Goldinger SM; Ugurel S; Gogas HJ; Egberts F; Berking C; Trefzer U; Loquai C; Weide B; Hassel JC; Gabriel SB; Carter SL; Getz G; Garraway LA; Schadendorf D;
Cancer Discov; 2014 Jan; 4(1):94-109. PubMed ID: 24265153
[TBL] [Abstract][Full Text] [Related]
60. Melanoma Treatments: Advances and Mechanisms.
Marzuka A; Huang L; Theodosakis N; Bosenberg M
J Cell Physiol; 2015 Nov; 230(11):2626-33. PubMed ID: 25899612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
